# A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice

> **NCT06606340** · — · ENROLLING_BY_INVITATION · sponsor: **Sarepta Therapeutics, Inc.** · enrollment: 300 (estimated)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** Eteplirsen
- **DRUG:** Golodirsen
- **DRUG:** Casimersen

## Key facts

- **NCT ID:** NCT06606340
- **Lead sponsor:** Sarepta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2019-01-07
- **Primary completion:** 2033-12-31
- **Final completion:** 2033-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06606340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06606340, "A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06606340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*